Immunome (NASDAQ:IMNM) Now Covered by Stephens

Research analysts at Stephens started coverage on shares of Immunome (NASDAQ:IMNM - Get Free Report) in a research note issued on Friday, MarketBeat.com reports. The firm set an "overweight" rating and a $30.00 price target on the stock. Stephens' price objective would indicate a potential upside of 132.92% from the stock's current price.

Several other equities analysts also recently commented on IMNM. Piper Sandler decreased their price objective on shares of Immunome from $27.00 to $23.00 and set an "overweight" rating on the stock in a report on Tuesday, August 13th. Wedbush reissued an "outperform" rating and issued a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has an average rating of "Buy" and a consensus target price of $29.17.

Immunome Stock Up 2.7 %

Shares of NASDAQ IMNM traded up $0.34 during trading hours on Friday, hitting $12.88. The company had a trading volume of 359,975 shares, compared to its average volume of 756,527. Immunome has a 1-year low of $6.93 and a 1-year high of $30.96. The firm's 50 day moving average is $13.43 and its 200-day moving average is $13.90. The stock has a market capitalization of $773.50 million, a P/E ratio of -1.63 and a beta of 1.82.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. On average, sell-side analysts predict that Immunome will post -1.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Max Rosett sold 14,380 shares of the company's stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares of the company's stock, valued at $760,090.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Max Rosett sold 14,380 shares of the firm's stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jean Jacques Bienaime bought 7,000 shares of the company's stock in a transaction on Friday, August 16th. The stock was bought at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the director now owns 16,615 shares of the company's stock, valued at approximately $231,613.10. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 8.60% of the company's stock.

Institutional Trading of Immunome

Several hedge funds and other institutional investors have recently modified their holdings of IMNM. Victory Capital Management Inc. grew its position in shares of Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock valued at $10,684,000 after purchasing an additional 237,497 shares in the last quarter. Northeast Financial Consultants Inc purchased a new position in Immunome during the 2nd quarter valued at about $883,000. The Manufacturers Life Insurance Company increased its position in shares of Immunome by 52.2% during the second quarter. The Manufacturers Life Insurance Company now owns 166,928 shares of the company's stock valued at $2,020,000 after buying an additional 57,242 shares during the period. AQR Capital Management LLC grew its stake in Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock valued at $194,000 after acquiring an additional 4,129 shares in the last quarter. Finally, AXA S.A. bought a new stake in Immunome during the 2nd quarter worth approximately $2,174,000. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.